December 20-22, 2019 new policy, new opportunity and new development forum of biochemical pharmacy and annual meeting of China biochemical pharmaceutical industry association were held in Beijing.
More than 100 member units of the association, more than 200 leaders, experts and enterprise representatives attended the meeting, sorted out and summarized the work of the association in the past year, and made plans for the future construction of the platform, aiming to better serve the enterprise members, take scientific and technological innovation as the starting point, innovate the service mode, and contribute to the health work.
2019 new policy, new opportunity and new development forum of biochemical pharmaceutical industry and annual meeting of China Biochemical Pharmaceutical Industry Association
Pose for a group photo
Chengdu Shengnuo Biotechnology Co., Ltd. was invited to participate in the Forum (hereinafter referred to as Shengnuo Biology), and won many honors in the conference.
Sinobio won the title of "excellent partner of biochemical and Biopharmaceutical Enterprises in 2019"
Xinnuo'an (atoxicban acetate injection), developed by sinobio, was recognized by China biochemical pharmaceutical industry association and honored as "excellent brand of biochemical and biological drugs in 2019"; in addition, sinobio also won the title of "excellent partner of biochemical and biological pharmaceutical enterprises in 2019" by China biochemical pharmaceutical industry association with first-class enterprise management and service.
In August this year, at the first China peptide industry forum and the founding meeting of polypeptide branch of China biochemical pharmaceutical industry association, Wen Yongjun, chairman of sinobio, made a report on the current situation of large-scale production of polypeptide drugs in China. The report gives a detailed introduction to the development origin of polypeptide industry in China. Combining with the development of history and technology, he analyzes the pain points and future prospects of polypeptide drug development in China at present, and with his years of deep cultivation and emotional sustenance in polypeptide drug industry, he has won the recognition and respect of the industry. "Full of feelings for the industry, never slack in the research" is the portrayal of the peptide industry of sinobio. In 2019, three types of products under research of sinobio have submitted the listing application, and the listing application of "blockbuster" lilalutide injection generic drug has been accepted by CDE on October 29, 2018.
Sinosat (atrociban acetate injection)
Won the honor of "excellent brand of biochemical and biological drugs in 2019"
With the rapid development of China's economy and science and technology, more and more pharmaceutical enterprises begin to pay attention to and invest a lot in peptide drugs. Peptide drugs have also entered the fast lane of development in China. Under the conditions of the application of various preparation technologies, the supply of key raw materials, and the gradual maturity of relevant supporting equipment, China also gradually has the ability to prepare synthetic peptide drugs on a large scale. At present, China's peptide drug industry is still in its infancy and growth stage, with great development potential. With the help of the "Dongfeng" of deepening the reform of drug review and approval system, China's peptide drug industry will also develop more vigorously and contribute more to China's health industry.
In the future, sinobio will make unremitting efforts and efforts to make due contributions to the development of China's health industry!
Shengnuo bio PRODUCT
Best sales manager contact
| Contacts | Roleagh |
|---|---|
| Tel | 86-28-88203630 |
| Fax | 86-28-88203630 |
| roleagh@gmail.com | |
| 2539328606 | |
| LEI LI |
About Shengnuo
Chengdu Shengnuo Biotechnology Co., Ltd. has "Chengdu polypeptide drug engineering technology research center" in Chengdu, mainly engaged in polypeptide, polypeptide drug and beauty peptide research. Our zero defect has passed the FDA certification, and now it has become the first-class professional peptide drug and product development, technology transfer, technical service and peptide drug industry in the scale production and export of China's parks.